A multicentric randomized phase II study evaluating dual targeting of the EGFR using the combination of cetuximab and afatinib versus cetuximab alone in patients with chemotherapy refractory wtKRAS metastatic colorectal cancer.
收藏NIAID Data Ecosystem2026-03-07 收录
官方服务：
资源简介：
Primary objectives: Non Progression rate at 6 months Primary endpoints: The primary endpoint non progression rate will be presented by the percentage of patients without progression at 6 months with the 95% confidence interval.
创建时间：
2012-05-15
相关数据集
暂无相关数据集
